Ascendis and BioMarin agree global Yuviwel patent settlement and licence
The binding term sheet resolves litigation between Ascendis Pharma and BioMarin while granting Ascendis a worldwide licence covering YUVIWEL and other navepegritide-related products.
BioMarin has agreed to grant Ascendis a non-exclusive, worldwide, royalty-bearing licence allowing it to continue researching, developing, manufacturing and commercialising navepegritide-related products without restriction.
Ascendis will pay BioMarin royalties equal to 20% of US net sales and 18% of net sales in the European Union, South Korea and Brazil from first commercial sale through 20 May 2030, while the companies will dismiss their respective proceedings.
Field | Content |
Alert Type | Industry Update |
Companies | Ascendis Pharma; BioMarin Pharmaceutical |
Agreement Type | Global settlement and licence agreement |
Product | YUVIWEL (navepegritide) |
Therapy Area | Achondroplasia and skeletal dysplasias |
Technology or Modality | C-type natriuretic peptide prodrug |
Geography | Global |
What Happened | On 31 August 2026, Ascendis Pharma and BioMarin entered into a binding term sheet setting out the terms of a global settlement and licence agreement related to YUVIWEL and other navepegritide-related products. The agreement is intended to resolve litigation and disputes between the companies. |
Licence Terms | BioMarin will grant Ascendis a non-exclusive, worldwide, royalty-bearing licence allowing Ascendis to continue researching, developing, manufacturing and commercialising navepegritide-related products without restriction. |
Royalty Terms | Ascendis will pay BioMarin royalties equal to 20% of US net sales and 18% of net sales in the European Union, South Korea and Brazil from first commercial sale in each territory through 20 May 2030. |
Why It Matters | The settlement removes a material intellectual-property dispute surrounding Ascendis' navepegritide franchise and provides a defined framework for continued global development and commercialisation. |
Supporting Context | BioMarin has also agreed to waive certain regulatory rights and exclusivities, dismiss proceedings and provide a covenant not to sue relating to the covered intellectual property. |
Potential Impact | Resolution of the dispute could reduce legal uncertainty around YUVIWEL and allow Ascendis to focus on commercial expansion and further development of navepegritide-related products. |
Key Takeaway | Ascendis has secured a worldwide licence and global settlement with BioMarin covering YUVIWEL and navepegritide-related products in exchange for defined royalty payments through May 2030. |
What to Watch | Execution of the definitive settlement agreement and the commercial trajectory of YUVIWEL across the covered markets. |
Primary Source | Ascendis Pharma |
Relevant Date | 31 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentários